Cantor Fitzgerald Analysts Give Neos Therapeutics (NEOS) a $20.00 Price Target

Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics (NASDAQ:NEOS) in a research report released on Monday morning. The firm currently has a buy rating on the stock.

A number of other brokerages have also issued reports on NEOS. Zacks Investment Research lowered shares of Neos Therapeutics from a buy rating to a sell rating in a research note on Thursday, October 19th. BidaskClub upgraded shares of Neos Therapeutics from a sell rating to a hold rating in a research note on Wednesday, December 27th. Cowen restated a buy rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. Finally, Wells Fargo & Co set a $14.00 price target on shares of Neos Therapeutics and gave the stock a buy rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $14.00.

Neos Therapeutics (NASDAQ NEOS) traded up $0.05 on Monday, hitting $10.40. 368,233 shares of the stock were exchanged, compared to its average volume of 323,392. The stock has a market capitalization of $301.57 and a price-to-earnings ratio of -3.04. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $13.15. The company has a debt-to-equity ratio of 4.01, a current ratio of 2.42 and a quick ratio of 2.14.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.22. The business had revenue of $6.70 million during the quarter. Neos Therapeutics had a negative net margin of 242.84% and a negative return on equity of 325.92%. analysts forecast that Neos Therapeutics will post -2.87 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board acquired a new position in Neos Therapeutics in the second quarter worth $102,000. Dynamic Technology Lab Private Ltd acquired a new position in Neos Therapeutics in the second quarter worth $118,000. JPMorgan Chase & Co. acquired a new position in Neos Therapeutics in the third quarter worth $120,000. Tudor Investment Corp ET AL acquired a new position in Neos Therapeutics in the second quarter worth $146,000. Finally, Rhumbline Advisers boosted its holdings in Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock worth $149,000 after purchasing an additional 2,441 shares during the period. 45.75% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/cantor-fitzgerald-analysts-give-neos-therapeutics-neos-a-20-00-price-target.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply